ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2213

Multi-omic Analysis of Macrophage Activation Syndrome Associated with sJIA Reveals a Potential Role of Type I Interferons in the Expansion of Cycling T Cells

Kailey Brodeur1, Liang Chen1, zhengping huang2, Yan Du1, Holly Wobma3, Maria Taylor4, Joyce Chang3, Megan Day-Lewis3, Fatma Dedeoglu3, Olha Halyabar3, Mindy Lo3, Jane W. Newburger5, Mary Beth F. Son3, Robert Sundel3, Peter Nigrovic3, lauren henderson3 and Pui Lee3, 1Boston Children's Hospital, Boston, MA, 2Guangdong Second Provincial Hospital, Guangzhou, China, 3Division of Immunology, Boston Children's Hospital, Boston, MA, 4Division of Immunology, Boston Children's Hospital, Brighton, MA, 5Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2022

Keywords: Innate Immunity Rheumatic Disease, interferon, Juvenile idiopathic arthritis, macrophage activation syndrome, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: Pediatric Rheumatology – Clinical II: JIA

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Macrophage activation syndrome (MAS) is a complication of systemic juvenile idiopathic arthritis (sJIA) characterized by cytokine storm and overt immune cell activation. We aim to further understand the immunologic landscape of sJIA and MAS.

Methods: We profiled peripheral blood mononuclear cells (PBMCs) from patients with active sJIA with or without MAS at the time of sampling and age-matched controls using bulk RNA sequencing (RNA-seq), single-cell RNA-seq, and mass cytometry. All patients with sJIA met ILAR diagnostic criteria and MAS was defined according to the 2016 Classification criteria for MAS complicating sJIA. Findings from RNA-seq and mass cytometry were validated using additional samples from patients with sJIA as well as patients with other inflammatory diseases by flow cytometry and in vitro T cell stimulation studies.

Results: Gene set enrichment analysis of bulk RNA-seq of PBMCs from patients with MAS (n = 9) revealed strong expression of genes associated with type I interferon signaling and T cell proliferation in addition to the expected type II IFN (IFN-g) signature based on gene set enrichment analysis. These features were rarely seen in age-matched healthy controls (n = 18) or patients with sJIA without MAS (n = 15). Single-cell RNA-seq confirmed the presence of type I and type II IFN signatures on all major PBMC subsets in patients with MAS (n = 8) while the T cell proliferation signature was localized to a population of Ki67+ cycling T cells with enhanced expression of IFN-g and genes involved in glycolysis, mTOR signaling and cytotoxicity (Figure 1).

Mass cytometry revealed that the cycling T cell population comprised of predominantly CD8+CD38+HLA-DR+ T cells and fewer CD4+CD38+HLA-DR+ T cells (Figure 2). We found that an expansion of CD38+HLA-DR+ T cells beyond 9% of CD8+ T cells or 4% of CD4+ T cells distinguished MAS from active sJIA, while a milder increase was generally seen in patients with sJIA without MAS compared to healthy controls (Figure 3). The degree of CD8+CD38+HLA-DR+ T cell expansion was also significantly greater in MAS compared to multi-system inflammatory syndrome in children (MIS-C) associated with COVID-19 (n = 17), acute viral infections (n = 15), Kawasaki disease (n = 7) and systemic lupus erythematosus (n = 9). In addition, stimulation of isolated T cells from healthy donors with IFN-I, but not IFN-II, augmented the effects of IL-12, IL-15 and IL-18 to generate CD8+CD38+HLA-DR+ T cells in vitro, while Janus kinase inhibition by ruxolitinib mitigated the impact of IFN-I treatment.

Conclusion: Our multi-omic analysis further details the expansion of the recently described CD8+CD38+HLADR+ T cells in MAS associated with sJIA. Our findings demonstrate a synergistic role of IFN-I in the generation of these cycling T cells and provide a mechanistic link between viral infections and MAS that may be targetable by JAK inhibition.

Supporting image 1

Figure 1. Single cell RNA-seq analysis of PBMCs from patients with sJIA with or without MAS. a) Uniform Manifold Approximation and Projection (UMAP) and annotation of immune cell populations. b) cluster plot of gene set enrichment analysis comparing the gene signatures of IFN-I, IFN-I and cell proliferation (G2M checkpoint and E2F targets). C) heatmap comparison of gene signatures across different lymphocyte populations in patients with sJIA-associated MAS.

Supporting image 2

Figure 2. UMAP display of mass cytometry analysis comparing PBMCs from healthy controls and patients with sJIA with or without MAS. Color denotes the expression of KI-67, HLA-DR and CD38) on a) CD8+ T cells and b) CD4+ T cells.

Supporting image 3

Figure 2. Quantification of cycling T cells in sJIA and other pediatric inflammatory diseases. a) Quantification of CD8+CD38+HLA-DR+ and b) CD4+CD38+HLA-DR+ T cells in healthy controls and patients with inactive sJIA, active sJIA without MAS, and active sJIA with MAS. c) Comparison of CD8+CD38+HLA-DR+ and d) CD4+CD38+HLA-DR+ T cells in healthy controls and patients with MAS, MIS-C, SLE, KD, and acute viral infections. * p < 0.05; *** p < 0.001


Disclosures: K. Brodeur, None; L. Chen, None; z. huang, None; Y. Du, None; H. Wobma, Immplacate Inc; M. Taylor, None; J. Chang, GlaxoSmithKline (GSK); M. Day-Lewis, None; F. Dedeoglu, Novartis; O. Halyabar, None; M. Lo, GlaxoSmithKlein(GSK); J. Newburger, None; M. Son, None; R. Sundel, None; P. Nigrovic, Bristol-Myers Squibb(BMS), Exo Therapeutics, Miach Orthopedics, Pfizer, Novartis, UpToDate, Cerecor, Brickell Bio; l. henderson, Sobi, Pfizer, Adaptive Biotechnologies, BMS; P. Lee, None.

To cite this abstract in AMA style:

Brodeur K, Chen L, huang z, Du Y, Wobma H, Taylor M, Chang J, Day-Lewis M, Dedeoglu F, Halyabar O, Lo M, Newburger J, Son M, Sundel R, Nigrovic P, henderson l, Lee P. Multi-omic Analysis of Macrophage Activation Syndrome Associated with sJIA Reveals a Potential Role of Type I Interferons in the Expansion of Cycling T Cells [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/multi-omic-analysis-of-macrophage-activation-syndrome-associated-with-sjia-reveals-a-potential-role-of-type-i-interferons-in-the-expansion-of-cycling-t-cells/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multi-omic-analysis-of-macrophage-activation-syndrome-associated-with-sjia-reveals-a-potential-role-of-type-i-interferons-in-the-expansion-of-cycling-t-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology